Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
For Ras oncoproteins to transform mammalian cells, they must be posttranslationally modified with a farnesyl group in a reaction catalyzed by the enzyme farnesyl:protein transferase (FPTase). Inhibitors of FPTase have therefore been developed as potential anticancer agents. These compounds reverse many of the malignant phenotypes of Ras-transformed cells in culture and inhibit the growth of tumor xenografts in nude mice. Furthermore, the FPTase inhibitor (FTI) L-744,832 causes tumor regression in mouse mammary tumor virus (MMTV)-v-Ha-ras transgenic mice and tumor stasis in MMTV-N-ras mice. Although these data support the further development of FTIs, it should be noted that Ki-ras is the ras gene most frequently mutated in human cancers. Moreover, Ki-RasB binds more tightly to FPTase than either Ha- or N-Ras, and thus higher concentrations of FTIs that are competitive with the protein substrate may be required to inhibit Ki-Ras processing. Given the unique biochemical and biological features of Ki-RasB, it is important to evaluate the efficacy of FTIs or any other modulator of oncogenic Ras function in model systems expressing this Ras oncoprotein. We have developed strains of transgenic mice carrying the human Ki-rasB cDNA with an activating mutation (G12V) under the control of the MMTV enhancer/promoter. The predominant pathological feature that develops in these mice is the stochastic appearance of mammary adenocarcinomas. High levels of the Ki-rasB transgene RNA are detected in these tumors. Treatment of MMTV-Ki-rasB mice with L-744,832 caused inhibition of tumor growth in the absence of systemic toxicity. Although FPTase activity was inhibited in tumors from the treated mice, unprocessed Ki-RasB was not detected. These results demonstrate the utility of the MMTV-Ki-rasB transgenic mice for testing potential anticancer agents. Additionally, the data suggest that although the FTI L-744,832 can inhibit tumor growth in this model, Ki-Ras may not be the sole mediator of the biological effects of the FTI.
Omer
C A
CA
Department of Cancer Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Chen
Z
Z
Diehl
R E
RE
Conner
M W
MW
Chen
H Y
HY
Trumbauer
M E
ME
Gopal-Truter
S
S
Seeburger
G
G
Bhimnathwala
H
H
Abrams
M T
MT
Davide
J P
JP
Ellis
M S
MS
Gibbs
J B
JB
Greenberg
I
I
Koblan
K S
KS
Kral
A M
AM
Liu
D
D
Lobell
R B
RB
Miller
P J
PJ
Mosser
S D
SD
O'Neill
T J
TJ
Rands
E
E
Schaber
M D
MD
Senderak
E T
ET
Oliff
A
A
Kohl
N E
NE
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D051231:Farnesyltranstransferase; D005260:Female; D011905:Genes, ras; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006801:Humans; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy*; D008324:Mammary Tumor Virus, Mouse; D008715:Methionine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D010641:Phenotype; D019076:Transgenes
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; C096898:L 744832; D008715:Methionine; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase